BACKGROUND: Data on 13 years (1997-2009) of outpatient penicillin use were collected from 33 European countries within the European Surveillance of Antimicrobial Consumption (ESAC) project and analysed in detail. METHODS: For the period 1997-2009, data on outpatient use of systemic penicillins aggregated at the level of the active substance were collected using the Anatomical Therapeutic Chemical (ATC)/defined daily dose (DDD) method (WHO, version 2011) and expressed in DDD per 1000 inhabitants per day (DID). For detailed analysis of trends over time, seasonal variation and composition of outpatient penicillin use in 33 European countries, we distinguished between narrow-spectrum penicillins (NSP), broad-spectrum penicillins (BSP), penicillinase-resistant penicillins (PRP) and combinations with β-lactamase inhibitors (COP). RESULTS: Total outpatient penicillin (ATC group J01C) use in 2009 varied by a factor of 3.8 between the countries with the highest (16.08 DID in France) and lowest (4.23 DID in the Russian Federation) use. COP represented 45.8%, BSP 40.7%, NSP 10.8% and PRP 2.6% of total European outpatient penicillin use. Total outpatient penicillin use significantly increased over time by 1.53 (SD 0.71) DID between 1997 and 2009. COP (mainly co-amoxiclav) increased by 2.17 (SD 0.40) DID, which was the result of its absolute increase as well as the observed shift from NSP and BSP towards COP. This increase exceeded 10% in 20 countries, where it coincided with a similar decrease in either BSP (15 countries) or NSP (5 countries). CONCLUSIONS: Penicillins represented the most widely used antibiotic subgroup in all 33 participating countries, albeit with considerable variation in their use patterns. For Europe, a continuous increase in overall penicillin use and of COP use was observed during the period 1997-2009.
BACKGROUND: Data on 13 years (1997-2009) of outpatientpenicillin use were collected from 33 European countries within the European Surveillance of Antimicrobial Consumption (ESAC) project and analysed in detail. METHODS: For the period 1997-2009, data on outpatient use of systemic penicillins aggregated at the level of the active substance were collected using the Anatomical Therapeutic Chemical (ATC)/defined daily dose (DDD) method (WHO, version 2011) and expressed in DDD per 1000 inhabitants per day (DID). For detailed analysis of trends over time, seasonal variation and composition of outpatientpenicillin use in 33 European countries, we distinguished between narrow-spectrum penicillins (NSP), broad-spectrum penicillins (BSP), penicillinase-resistant penicillins (PRP) and combinations with β-lactamase inhibitors (COP). RESULTS: Total outpatientpenicillin (ATC group J01C) use in 2009 varied by a factor of 3.8 between the countries with the highest (16.08 DID in France) and lowest (4.23 DID in the Russian Federation) use. COP represented 45.8%, BSP 40.7%, NSP 10.8% and PRP 2.6% of total European outpatientpenicillin use. Total outpatientpenicillin use significantly increased over time by 1.53 (SD 0.71) DID between 1997 and 2009. COP (mainly co-amoxiclav) increased by 2.17 (SD 0.40) DID, which was the result of its absolute increase as well as the observed shift from NSP and BSP towards COP. This increase exceeded 10% in 20 countries, where it coincided with a similar decrease in either BSP (15 countries) or NSP (5 countries). CONCLUSIONS:Penicillins represented the most widely used antibiotic subgroup in all 33 participating countries, albeit with considerable variation in their use patterns. For Europe, a continuous increase in overall penicillin use and of COP use was observed during the period 1997-2009.
Authors: Shiona K Glass-Kaastra; Rita Finley; Jim Hutchinson; David M Patrick; Karl Weiss; John Conly Journal: Can J Infect Dis Med Microbiol Date: 2014-03 Impact factor: 2.471
Authors: João H O S Pereira; Ana C Reis; Olga C Nunes; Maria T Borges; Vítor J P Vilar; Rui A R Boaventura Journal: Environ Sci Pollut Res Int Date: 2013-07-31 Impact factor: 4.223
Authors: Meera Tandan; Akke Vellinga; Robin Bruyndonckx; Paul Little; Theo Verheij; Chris C Butler; Herman Goossens; Samuel Coenen Journal: Antibiotics (Basel) Date: 2017-12-13
Authors: Philip Hei Li; Leonard Quok Chean Siew; Iason Thomas; Timothy J Watts; Kok Loong Ue; Krzysztof Rutkowski; Chak-Sing Lau Journal: World Allergy Organ J Date: 2019-09-16 Impact factor: 4.084
Authors: M H Nguyen; R Fornes; N Kamau; H Danielsson; S Callens; E Fransson; L Engstrand; R Bruyndonckx; N Brusselaers Journal: J Antimicrob Chemother Date: 2022-04-27 Impact factor: 5.758
Authors: Annemieke K van den Broek; Reinier M van Hest; Kamilla D Lettinga; Afra Jimmink; Fanny N Lauw; Caroline E Visser; Jan M Prins Journal: Antimicrob Resist Infect Control Date: 2020-02-22 Impact factor: 4.887